]>
IRCT138808062641N1 IRCT 2010-01-21 Tehran University of Medical Sciences The effectiveness of 1 mg/day Colchicine in the treatment of patients with ocular involvement in Behcet's Disease The effectiveness of 1 mg/day Colchicine in the treatment of patients with ocular involvement in Behcet's Disease 2010-01-21 anticipated 80 Complete https://irct.ir/trial/2453 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment. 4 Ocular involvement in Behcet's disease. Colchicine 1mg/day during one year PO.
public Bahar Sadeghi
Shariati hospital
Tehran Iran (Islamic Republic of) +98 21 8802 6956 bahar@bahars.net Rheumatology Research Center scientific Prof. Fereydoun Davatchi
Shariati hospital
Tehran Iran (Islamic Republic of) +98 21 8802 6956 fddh@neda.net Rheumatology Research Center Iran (Islamic Republic of) Inclusion criteria: diagnosed Behcet's disease according to Iran's diagnostic tree criteria, signing the informed consent, not being pregnant or breast feeding, no history of malignancy, age more than16, posterior uveitis or retinitis in latest ophtalmological visit Exclusion criteria: blood dyscrasia, pregnancy, low compliance 17 years 70 years Both M35.2 behcet's disease Treatment - Drugs Colchicine 1mg/day during one year PO Decrease/or not relapsing of ocular inflammatory index. Timepoint: 3 months. Method of measurement: ophtalmologist's record. Decrease/or not relapsing ocular IBDDAM. Timepoint: 3 months. Method of measurement: Ophtalmologist's record. Retinal inflammatory index. Timepoint: 3 months. Method of measurement: Ophtalmologist's record. Posterior chamber inflammatory index. Timepoint: 3 months. Method of measurement: Ophtalmologist's record. Tehran University of Medical Sciences Approved 2009-10-26 EDRC's Commettee of Medical Ethics Shariati hospital, Kargar Ave. Tehran Iran (Islamic Republic of)